Latest Information Update: 10 Apr 2003
At a glance
- Originator Ontogen
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 10 Apr 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 03 Aug 2000 Preclinical development for Diabetes mellitus in USA (Unknown route)